HTLV-I replication in unfractionated PBMCs, CD8− PBMCs, and CD8− PBMCs reconstituted with autologous or allogeneic CD8+ T cells
| Carrier . | p19 Ag level in culture supernatant (pg/mL) . | |||||
|---|---|---|---|---|---|---|
| Unfract PBMCs . | CD8−PBMCs . | CD8− PBMCs plus* . | ||||
| auto CD8+ cells . | allo CD8+ cells† . | |||||
| (9:1) . | (4:1) . | (9:1) . | (4:1) . | |||
| 1 | 47 | 212 | 115 (46%)‡ | 25 (88%) | 180 (15%) | 77 (64%) |
| 2 | 36 | 465 | 190 (59%) | 28 (94%) | 358 (23%) | 228 (51%) |
| 3 | 52 | 1120 | 512 (54%) | 60 (95%) | 2540 (—) | 602 (46%) |
| 4 | <25 | 240 | 152 (37%) | 35 (85%) | 140 (42%) | 70 (71%) |
| 5 | 207 | 526 | 529 (—) | 272 (48%) | 393 (25%) | 312 (41%) |
| 6 | 91 | 493 | 480 (3%) | 111 (78%) | 530 (—) | 242 (51%) |
| Carrier . | p19 Ag level in culture supernatant (pg/mL) . | |||||
|---|---|---|---|---|---|---|
| Unfract PBMCs . | CD8−PBMCs . | CD8− PBMCs plus* . | ||||
| auto CD8+ cells . | allo CD8+ cells† . | |||||
| (9:1) . | (4:1) . | (9:1) . | (4:1) . | |||
| 1 | 47 | 212 | 115 (46%)‡ | 25 (88%) | 180 (15%) | 77 (64%) |
| 2 | 36 | 465 | 190 (59%) | 28 (94%) | 358 (23%) | 228 (51%) |
| 3 | 52 | 1120 | 512 (54%) | 60 (95%) | 2540 (—) | 602 (46%) |
| 4 | <25 | 240 | 152 (37%) | 35 (85%) | 140 (42%) | 70 (71%) |
| 5 | 207 | 526 | 529 (—) | 272 (48%) | 393 (25%) | 312 (41%) |
| 6 | 91 | 493 | 480 (3%) | 111 (78%) | 530 (—) | 242 (51%) |
HTLV-I = human T-cell lymphotropic virus type I; PBMCs = peripheral blood mononuclear cells; unfract = unfractionated. PBMCs were obtained from 3 pairs of HTLV-I carriers (1–6). Three million unfractionated PBMCs or CD8− PBMCs were propagated in RPMI 1640 medium supplemented with 10% fetal bovine serum. Cell-free culture supernatants were collected on day 7 of culture, and p19 levels were determined by ELISA.
Where indicated, CD8− PBMCs were reconstituted with autologous or allogeneic CD8+ T cells at the indicated ratio.
Allogeneic cultures were performed between carriers 1 and 2, carriers 3 and 4, and carriers 5 and 6.
Percentage suppression is expressed as: 100-(p19 Ag level of CD8− PBMC reconstituted with CD8+ T cells/p19 Ag level of CD8− PBMC alone).